A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization

A Phase 2 Randomized, Double-blind, Double-dummy Efficacy, Safety And Tolerability Study Of Iv Sulopenem With Switch To Oral Pf-03709270 Compared To Ceftriaxone With Step Down To Amoxicillin/Clavulanate Potassium (Augmentin) In Subjects With Community Acquired Pneumonia (Cap) Requiring Hospitalization

The purpose of this study is to test if intravenous sulopenem and an oral drug, PF-03709270 are safe and effective in patients that are hospitalized with community acquired pneumonia.

Inclusion Criteria:

• Hospitalized male or female patients 18 years of age or older.
• Female patients of childbearing potential must not be pregnant.
• Must exhibit at least two pre-specified clinical symptoms/signs of pneumonia.
• Must require hospitalization for the pneumonia.
• Chest Xray must be suggestive of a pneumonia.

Exclusion Criteria:

• Hospital or ventilator associated pneumonia.
• Patients with cystic fibrosis, pneumocystis carinii pneumonia or active tuberculosis.
• Previous treatment for the current pneumonia episode received for more than 24 hours.
• Allergies to penems or beta lactams.